Equities

abrdn Life Sciences Investors

HQL:NYQ

abrdn Life Sciences Investors

Actions
FinancialsClosed End Investments
  • Price (USD)15.55
  • Today's Change0.01 / 0.06%
  • Shares traded79.73k
  • 1 Year change+23.51%
  • Beta0.7048
Data delayed at least 15 minutes, as of Sep 20 2024 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

abrdn Life Sciences Investors (the Fund), formerly Tekla Life Sciences Investors, is a non-diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, and agriculture and environmental management. The Fund invests primarily in securities of public and private companies, which have the potential for above-average growth. The Fund invests up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund's investment adviser is abrdn Inc.

  • Revenue in USD (TTM)3.63m
  • Net income in USD38.81m
  • Incorporated1992
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Advent Convertible and Income Fund-100.00bn-100.00bn408.55m--------------------------------------------------------------
Invesco Advantage Municipal Income Tr II32.02m34.07m410.31m0.0012.040.9369--12.820.76720.76720.7219.860.0452--9.68--4.800.91144.870.918251.3564.36106.4122.51----0.3692297.36-0.6983-3.22153.3817.14---8.82
BlackRock MuniYield NewYork Qlty Fnd Inc-100.00bn-100.00bn411.48m0.00------------------------------------------------------------
Horizon Kinetics Holding Corp3.26m-4.22m414.63m8.00--6.20--127.03-6.48-0.7325.023.590.48863.424.53408,000.00-63.11-23.70-87.48-28.2944.2141.79-129.17-27.284.24--0.00--14.19-37.9748.60------
Allspring Income Opportunities Fund45.74m38.34m414.83m--10.760.9754--9.070.65270.65270.77417.200.0733--3.24--6.142.696.242.7465.5275.3183.8143.54----0.3077219.9710.25-1.98478.260.8261---2.73
Highland Opportunities and Income Fund43.12m-23.26m415.20m----0.4918--9.63-0.3383-0.33830.641114.880.0413--1.40---2.233.25-2.273.4072.2175.30-53.9554.33--0.49230.0081154.10-47.15---145.58------
Eaton Vance Tax-Managed Buy-Wrte Incm Fd6.88m58.73m419.47m0.007.140.9496--60.952.002.000.234315.040.0158--12.96--13.478.3513.528.3738.2845.13853.44470.07----0.0093.17-2.53-3.18207.42-----5.72
Eaton Vnc Tax-Advtgd Glbl Dvdnd Oppnt Fd-100.00bn-100.00bn423.96m--------------------------------------------------------------
abrdn Life Sciences Investors3.63m38.81m425.30m--10.960.9643--117.011.421.420.132916.130.0083--59.13--8.871.548.991.56-36.65-68.311,067.62238.14----0.00514.0115.8911.99121.37-4.85----
Voya Global Equity Div and Prem Oppty Fd35.01m30.48m439.30m--10.600.9462--12.550.52570.52570.74165.890.0737--13.00--6.424.206.484.2688.7683.4387.0581.42----0.00132.08204.13--339.84-----8.09
Duff & Phelps Utlty and Infrstct Fnd Inc16.27m-7.51m439.47m----1.07--27.00-0.1967-0.19670.426310.800.0268--5.09---1.241.57-1.251.57-6.9022.50-46.1458.59---0.24680.2795455.99-4.24-8.38-204.11-----2.09
Flaherty & Crumrine Dynmc Prf&Inm Fd Inc47.44m71.82m439.52m--6.121.01--9.263.503.502.3121.180.0687--7.14--10.392.6710.432.6753.8472.92151.4044.32----0.3884175.512.381.37110.36-----4.17
Nuveen Multi-Asset Income Fund29.36m46.16m440.55m--9.540.9733--15.011.381.380.878413.540.0442--7.71--6.95--7.94--48.16--157.20------0.2852--1.31--137.44------
Guggenhm Txble Mcpl Bnd & Invt Gd Dt Trt-100.00bn-100.00bn442.21m--------------------------------------------------------------
Diamond Hill Investment Group Inc142.33m41.23m442.86m129.0011.092.8310.743.1114.5214.5250.0056.890.6275--7.491,103,345.0017.6118.7720.4723.8297.6497.7228.0734.42----0.0075.69-11.51-1.254.43-1.89-51.17--
Data as of Sep 20 2024. Currency figures normalised to abrdn Life Sciences Investors's reporting currency: US Dollar USD

Institutional shareholders

23.88%Per cent of shares held by top holders
HolderShares% Held
Saba Capital Management LPas of 30 Jun 20243.43m12.54%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024490.14k1.79%
1607 Capital Partners LLCas of 30 Jun 2024419.28k1.53%
Karpus Management, Inc.as of 30 Jun 2024404.38k1.48%
Allspring Global Investments LLCas of 30 Jun 2024346.62k1.27%
Needham Investment Management LLCas of 30 Jun 2024341.82k1.25%
AQR Arbitrage LLCas of 30 Jun 2024337.20k1.23%
Flagship Harbor Advisors LLCas of 31 Mar 2024283.83k1.04%
RPO LLCas of 30 Jun 2024259.28k0.95%
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 30 Jun 2024217.03k0.79%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.